6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide
-
6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide
structure -
-
CAS No:
801312-28-7
-
Formula:
C27H26N4O5S
-
Chemical Name:
6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide
-
Synonyms:
6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide;GSK-256066;GSK2606416;6-(3-(dimethylcarbamoyl)phenylsulfonyl)-4-(3-methoxyphenylamino)-8-methylquinoline-3-carboxamide;6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide GSK-256066;6-(3-(Dimethylcarbamoyl)phenylsulfonyl)-4-(3-methoxyphenylamino)-8-methylquinoline-3-carboxami
- Categories:
-
CAS No:
Description
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7.IC50 value: 3.2 pM [1]Target: PDE4Bin vitro: GSK256066 is a slow and tight binding inhibitor of PDE4B with apparent IC50 of 3.2 pM. GSK256066 is an extremely potent inhibitor of LPS-stimulated TNFα production in PBMCs with pIC50 of 11.0 and IC50 of 10 pM and human whole-blood cultures with pIC50 of
6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide Basic Attributes
518.58414
518.162415
Safety Information
P260, P261, P271, P284, P304+P340, P310, P312, P314, P320, P403+P233, P405, P501
H330
6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide Use and Manufacturing
Quinoline derivative and a potential selective PDE4 phosphodiesterase inhibitor to treat prophylaxis or treatment of clinical conditions such as inflammatory or allergic diseases.
Recommended Suppliers of 6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide
-
US
6 YRS
Business licensed Certified factoryManufactory Supplier of Coenzymes,Inhibito,Enzymes,Zymogens,Substrates
Latest News on 6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide hydrochloride
801315-14-0
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141 Formula
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Structure
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
What is C-REACTIVE PROTEIN FRAGMENT 77-82
130349-01-8
-
What is Sildenafil
139755-83-2
6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide
SDSRequest for Quotation